NOVALIQ-GMBH
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the launch of NovaTears® in New Zealand and registrational approval in Australia.
According to McCarty, the prevalence of dry eye disease (DED) is approximately 7.4 percent in Australia and New Zealand; counting for more than 2 million people suffering from dry eye disease in this region1 .
In March 2017, Novaliq and AFT Pharmaceuticals (AFT) signed an exclusive licensing partnership agreement for the commercialization of NovaTears® across Australasia. AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed on ASX and NZX, will commercialize NovaTears®, the first and only water-free topical eye drop treatment specifically developed to treat patients with DED. According to the latest TFOS DEWS II definition and classification report2 , patients with tear-lipid dysfunction account for the greater proportion of all DED patients and no adequate treatment option was available in New Zealand until now.
NovaTears® immediately stabilizes the lipid layer without causing vision blurring. Clinically validated in four clinical trials, NovaTears® eye drops are proven to be safe and effective. Results from these trials showed that NovaTears® is safe and efficacious for treating the signs and symptoms of DED and Meibomian Gland Dysfunction (MGD). A large number of objective disease parameters such as tear film breakup time, corneal and conjunctival fluorescein staining but also a number of expressible Meibomian glands and Meibom quality have been improved under NovaTears® treatment.
“NovaTears® is a first-in-class treatment for this common and highly underserved ophthalmic disease,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “NovaTears® is a clinically validated treatment that significantly improves signs and symptoms of patients suffering from dry eye disease. We know from our clinical studies that NovaTears® immediately stabilizes the lipid layer and restores the natural tear film of the eye over time. I am confident that dry eye patients in Australasia will greatly benefit from this breakthrough innovation.”
For patients, NovaTears® eye drops combine high efficacy with great comfort. Signs and subjective symptoms of DED are significantly reduced without causing blurry vision after application. NovaTears® is pure, and therefore has no side effects related to preservatives or other additives.
For healthcare professionals, NovaTears® expands the established treatment portfolio with a new option of a water-free formulation and a new mode of action to treat more patients effectively. NovaTears® increases patients’ compliance due to proven clinical effectiveness and tolerability.
“We are thrilled to be able to offer patients a novel ophthalmic treatment that addresses signs and symptoms of evaporative DED and MGD,” said Hartley Atkinson, PhD, CEO, AFT. “NovaTears® is a first-in-class, water-free and preservative-free treatment that strengthens the lipid layer of the tear film thereby preventing evaporation. It is a welcome addition to our eye care line, one that will provide superior benefits to patients.”
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com .
About AFT Pharmaceuticals – AFT founded in 1997 is an Auckland, New Zealand-based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT has been listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices.
Sources:
1. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The
epidemiology of dry eye in Melbourne, Australia. Ophthalmology
1998;105(6):1114-9
2. TFOS DEWS II Definition and Classification
Report 2017
View source version on businesswire.com: http://www.businesswire.com/news/home/20171030005362/en/
Contact:
NOVALIQ GmbH
For US:
Michael O’Rourke, + 1 813 323 1438
Strategic
Consultant, ext.
mrourke@novaliq.com
or
For
EU/Asia:
Heidrun Kirsch, + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AmTrust Strengthens Its Position in Türkiye After Successful Year of Growth19.5.2025 10:00:00 CEST | Press release
AmTrust International, a global specialty insurer and reinsurer, has announced significant progress in its Turkish operations following the successful opening of its office in Istanbul last year. This growth aligns with AmTrust’s ongoing strategic goal of enhancing underwriting profitability and expanding its geographical footprint in the credit protection and affinity sector. Over the past year, AmTrust’s team in Türkiye, led by General Manager Erdinc Karayazlik, has successfully strengthened the company’s foothold in the specialty market. With 20 years of experience in senior insurance distribution roles across Türkiye, the Middle East, Europe, and Africa, and supported by his experienced team, Karayazlik has been instrumental in driving initiatives that have further developed AmTrust’s offerings, including mortgages, credit protection and rent guarantees while working across geographies. “I’m thrilled with the progress we’ve made since our establishment in Türkiye. Our focus on the
GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions19.5.2025 09:29:00 CEST | Press release
GIGABYTE, a global leader in IT and AI infrastructure, is set to showcase its full-stack AI solutions at COMPUTEX 2025 from May 20–23, under the theme “Omnipresence of Computing: AI Forward.” With end-to-end innovations spanning cloud, data center, edge, and application, GIGABYTE is redefining what computing can achieve in the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514218509/en/ GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions Total Data Center Solutions: From Hardware to Cluster Management At the heart of the showcase is GIGAPOD, GIGABYTE’s high-density, rack-scale infrastructure for AI workloads. Integrated with GPM, GIGABYTE’s in-house management platform, the solution enables unified orchestration of resources, from node to rack to cluster. This powerful combination supports rapid deployment, workload optimization, and real-time system monitoring—f
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 08:00:00 CEST | Press release
New GUINNESS WORLD RECORDS Title for Most Accurate Value of Pi - 300 Trillion Digits Calculated Using KIOXIA NVMe™ SSDs Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 08:00:00 CEST | Press release
Businesses using NetApp AIPod can accelerate AI agents and speed up retrieval of relevant information NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data est
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom